Publications by authors named "Mathew Simcock"

Claim this Profile
E
Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA-JMML-001 trial.
Franco Locatelli, Karin Belander Strålin, Irene Schmid, Julián Sevilla, Owen P Smith, Mathew Simcock

Pediatr Blood Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.
Maureen M O'Brien, Todd A Alonzo, Todd M Cooper, John E Levine, Patrick A Brown, Mathew Simcock

Pediatr Blood Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Charlotte M Niemeyer, Christian Flotho, Daniel B Lipka, Jan Starý, Claudia Rössig, Mathew Simcock

Blood Adv· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors.
Jason Fangusaro, Maria Giuseppina Cefalo, Maria Luisa Garré, Lynley V Marshall, Maura Massimino, Mathew Simcock

Front Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Loredana Amoroso, Victoria Castel, Gianni Bisogno, Michela Casanova, Catalina Marquez-Vega, Mathew Simcock

Eur J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Lucas Moreno, Michela Casanova, Julia C Chisholm, Pablo Berlanga, Pascal B Chastagner, Mathew Simcock

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Meletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Mathew Simcock

Blood· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of distinct metastasizing preferences of different melanoma subtypes.
Nicola L Schoenewolf, Benedetta Belloni, Mathew Simcock, Sabina Tonolla, Pascale Vogt

Eur J Dermatol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
Martin Früh, Richard Cathomas, Marco Siano, Gregor Tscherry, Alfred Zippelius, Mathew Simcock

Clin Lung Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Peter Schraml, Adriana von Teichman, Daniela Mihic-Probst, Mathew Simcock, Adrian Ochsenbein

Oncol Rep· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Pirus Ghadjar, Mathew Simcock, Frank Zimmermann, Michael Betz, Stephan Bodis

Radiother Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High dose-rate versus low dose-rate brachytherapy for lip cancer.
Pirus Ghadjar, Beat Bojaxhiu, Mathew Simcock, Dario Terribilini, Bernhard Isaak

Int J Radiat Oncol Biol Phys· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.
Nicola L Schoenewolf, Reinhard Dummer, Daniela Mihic-Probst, Holger Moch, Mathew Simcock

Case Rep Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Pirus Ghadjar, Mathew Simcock, Gabriela Studer, Abdelkarim S Allal, Mahmut Ozsahin

Int J Radiat Oncol Biol Phys· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Axel Madlung, Mathew Simcock, Pirus Ghadjar

Cancer· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Jakob R Passweg, Aristoteles A N Giagounidis, Mathew Simcock, Carlo Aul, Christiane Dobbelstein

J Clin Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of small lymph node metastases with evidence of extracapsular extension: clinical implications in patients with head and neck squamous cell carcinoma.
Pirus Ghadjar, Mathew Simcock, Heide Schreiber-Facklam, Yitzhak Zimmer, Ruth Gräter

Int J Radiat Oncol Biol Phys· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
Dieter Koeberle, Michael Montemurro, Panagiotis Samaras, Pietro Majno, Mathew Simcock

Oncologist· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Roger von Moos, Arnaud Roth, Thomas Ruhstaller, Lucas Widmer, Catrina Uhlmann, Mathew Simcock

Onkologie· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative analysis of extracapsular extension of metastatic lymph nodes and its significance in radiotherapy planning in head and neck squamous cell carcinoma.
Pirus Ghadjar, Heide Schreiber-Facklam, Ruth Gräter, Christina Evers, Mathew Simcock

Int J Radiat Oncol Biol Phys· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers.
Pirus Ghadjar, Wieslawa Blank-Liss, Mathew Simcock, Ivan Hegyi, Karl T Beer

Clin Exp Metastasis· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
Christoph A Fux, Andri Rauch, Mathew Simcock, Heiner C Bucher, Bernard Hirschel

Antivir Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98).
Reinhard Zenhäusern, Mathew Simcock, Alois Gratwohl, Urs Hess, Mario Bargetzi

Haematologica· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Christoph A Fux, Mathew Simcock, Marcel Wolbers, Heiner C Bucher, Bernard Hirschel

Antivir Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Mathew Simcock, Monika Blasko, Urs Karrer, Barbara Bertisch, Miklos Pless

Antivir Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis